NeuralBase AI Ltd. Advances HeartEase App Development for Android and iOS
NeuralBase AI Ltd. announces the completion of the Android version of its HeartEase app, marking a significant step towards its market release and the upcoming iOS version testing.
NeuralBase AI Ltd., operating under its enterprise brand BMP AI, has reached a pivotal development milestone with its HeartEase app, designed to offer AI-powered cardiovascular and emotional health insights. The Android version of the app is now complete and in the final stages of testing, with a public release anticipated in the coming weeks. The iOS version is set to follow, entering testing shortly after the Android launch.
HeartEase utilizes NeuralBase AI’s proprietary AI platform to deliver intelligent monitoring, real-time feedback, and personalized wellness recommendations. This innovative approach aims to support proactive wellness management by analyzing behavioral insights and biometric data. The app’s development progress signifies NeuralBase AI’s commitment to enhancing digital health solutions and expanding its AI-powered ecosystem.
Vighnesh Dobale, Chief Executive Officer of NeuralBase AI Ltd., emphasized the importance of this milestone in bringing HeartEase to the market. The completion of the Android version and the preparation for iOS testing are critical steps in ensuring feature parity and performance consistency across platforms. The app’s launch is expected to validate the technology stack in real-world conditions, gather user feedback for further refinements, and establish a foundation for potential strategic partnerships with healthcare providers and wearable technology companies.
NeuralBase AI Ltd. is focused on scaling its digital health ecosystem as part of its broader mission to support enterprise wellness and preventive health diagnostics. The company plans to share updates on HeartEase’s release schedule and platform enhancements as testing progresses. Additional information about NeuralBase AI Ltd. can be found at https://www.neuralbase.ai or by visiting https://www.sec.gov.
The anticipated closing of the HeartEase transaction by September 15, 2025, underscores the company’s forward momentum in the digital health space. NeuralBase AI Ltd. remains committed to transparency and compliance, with all necessary disclosures to be filed with the Securities & Exchange Commission via EDGAR.